摘要
本文报告了动脉灌注化疗药物治疗晚期肺癌患者101例,将其中资料完整的80例分5组,比较近期疗效。①支气管动脉灌注(BAI)丝裂霉素组17例,完全缓解(CR)11.8％,部分缓解率(PR)29.4％,CR+PR为41.2％;②BAI给顺铂11例,CR9.1％,PR54.5％,CR+PR为63.6％;③环磷酰胺、阿霉素、顺铂(CAP方案)BAI21例,CR33.3％、PR42.9％,CR+PR为76.2％;④CAP方案BAI+放疗20例,CR55.0％、PR40.0％,CR+PR为95.0％;⑤CAP方案胸主动脉给药(TAI)+放疗组11例,CR45.4％,PR36.4％,CR+PR为81.8％。动脉灌注化疗药物可减轻病人痛苦,改善生存质量,对小细胞肺癌亦有一定疗效。文中还讨论了其抗肿瘤作用的机理及顺铂的药代动力学问题。
This article presents 80 cases out of 101 cases of advanced lung cancer treated by intra-arterial infusion. Based on therapeutic regimen these cases were divided into 5 groups and the therapeutic effects were compared. 1) Bronchial arterial infusion(BAI) plus MMC group (17 cases): CR 11.8%, PR 29.4%, and CR+PR 41.2%; 2) BAI plus CDDP group (11 cases):CR 9.1%, PR 54.5%, and CR+PR 63.6%; 3) BAI plus CAP regimen(CTX 100 mg, Adr 80 mg, CDDP 60 mg) group (21 cases): CR 33.3%, PR 42.9%,and CR + PR 76.2%; 4) BAI plus CAP reginen combined with radiotherapy group (20 cases); CR 55.0%, PR 40.0%, CR + PR 95.0%; and 5) Thoracic aorta infusion (TAI) plus CAP regimen combined with radiotherapy group (11 cases):CR 45.4%, PR 36.4%,and CR+PR 81.8%. The mechanism of therapeutic effects of BAI or TAI plus CAP regimen combined with radiotherapy and pharmakinetics of CDDP are also disscused.
出处
《同济医科大学学报》
CSCD
北大核心
1993年第1期20-23,79,共4页
Acta Universitatis Medicinae Tongji
关键词
肺肿瘤
环磷酰胺
阿霉素
顺铂
lung cancer
antineoplastic agents, combined
perfusion, regional
bronchial arteries
